RVL Pharmaceuticals PLC reports results for the quarter ended in March - Earnings Summary

RVL Pharmaceuticals

11/05/2023 14:33

* RVL Pharmaceuticals PLC  RVLP.OQ  reported a quarterly
adjusted
loss of 12 cents​​ per share for the quarter ended in March. The
mean expectation of five analysts for the quarter was for a loss
of 12 cents per share.
    * Revenue fell 58.8% to $8.83 million from a year ago;
analysts
expected $9.44 million. 
    * RVL Pharmaceuticals PLC's reported EPS for the quarter was
a
loss of 12 cents​.
    * The mean earnings estimate of analysts had fallen by
about 12.2%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * RVL Pharmaceuticals PLC shares had fallen by 25.4% this
quarter and lost 24.1% so far this year.
    * The company reported a quarterly loss of $11.61 million.
    * Wall Street's median 12-month price target for RVL
Pharmaceuticals PLC is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.12          -0.12          Met
 Dec. 31 2022      -0.16          -0.18          Missed
 Sep. 30 2022      -0.16          -0.16          Met
 Jun. 30 2022      -0.21          -0.14          Beat